Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

A New Cancer Treatment That Can Bind to Both Cancer Cells and T Cells Has Been Developed

A New Cancer Treatment That Can Bind to Both Cancer Cells and T Cells Has Been Developed

The 10 hallmarks of cancer include learning to become invisible to the immune system. Immunotherapies offer an effective treatment opportunity by enabling the immune system to recognize cancer cells. In May 2018, PNAS published a study showing that a newly designed antibody drug binds both to a cancer cell and to an immune T cell, enabling destruction of the cancer cell.

Two Features of This Antibody:

  • One part of the antibody binds to ROR1, a highly active receptor on cancer cells. ROR1 is a tyrosine kinase receptor on the surface of cancer cells. ROR1 is active in normal cells during embryonic development, but loses its activity in adulthood. Studies to date have detected active ROR1 receptors in breast, lung, ovarian and blood cancers. Her2 -negative breast cancer patients have high ROR1 receptor activity.
  • The second part of the antibody binds to T cells and activates them. T cells are the most important white blood cells that destroy cancer cells.
ror1 receptor cancer immunotherapy with bispecific antibody treatment

What Does This Study Tell Us?

  • A new antibody was designed that simultaneously binds to cancer cells and activates T cells.
  • Conventional antibody treatments bind to cancer cells but cannot activate T cells. These newly designed dual-function antibodies could effectively destroy cancer cells.
  • These types of antibodies may be used particularly against Her2-negative breast cancer.

These dual-function antibodies were produced using genetic engineering technologies and are called bispecific antibodies in oncology. Among bispecific antibody treatments, a type of immunotherapy, only one drug has so far received FDA approval: blinatumomab [bispecific T-cell engagers (BiTEs)], which binds to CD3 on T cells on one side and CD19 molecules on tumor cells on the other, and is used to treat acute lymphoblastic leukemia.

Sources

Junpeng Qi, Xiuling Li, Haiyong Peng ve ark.
Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.
PNAS May 29, 2018.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

A New Cancer Treatment That Can Bind to Both Cancer Cells and T Cells Has Been Developed

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy